Sigma-Tau Pharmaceuticals Seeking FDA Approval of Medicine for Rare Genetic Disease Affecting Less Than 100 Americans

Published: Jul 09, 2008

GAITHERSBURG, MD--(Marketwire - July 9, 2008) - Sigma-Tau Pharmaceuticals, Inc. is pleased to announce the acquisition of Chenofalk® (chenodeoxycholic acid) from the Germany-based, Dr. Falk Pharma GmbH. Chenofalk® is approved in Germany for the dissolution of gallstones, and Sigma-Tau's German affiliate, Sigma-Tau Arzneimittel GmbH, will immediately assume distribution of this important medicine, ensuring there is no interruption in availability to patients.

Back to news